Drug intelligence / Profile preview

trifluoromethionine

Development stage
Preclinical
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01

Overview

Trifluoromethionine is a non-proteinogenic amino acid and a fluorinated analogue of methionine in which the methyl group of methionine is replaced by a trifluoromethyl group. It is classified as an organofluorine compound and belongs to the class of L-alpha-amino acids. Trifluoromethionine acts as an antimicrobial agent with demonstrated in vitro toxicity against anaerobic protozoan parasites such as Trichomonas vaginalis and certain bacterial strains expressing methionine gamma lyase (MGL). Its mechanism involves targeting enzymes like methionyl-tRNA synthetase (methionyl-tRNA ligase), methionine aminopeptidase, and particularly relies on the presence of MGL for its cytotoxic effects. Resistance can develop through downregulation or absence of MGL activity[5][7][8]. The compound has been used primarily in research settings to study protein engineering, enzyme mechanisms, and antimicrobial activity rather than as an approved pharmaceutical drug[1][2][5].

Other names
trifluoro-L-methionine(S)-2-amino-4-((trifluoromethyl)thio)butanoic acidL-homocysteine S-(trifluoromethyl)764-52-3
02

Targets

METAP2 (Methionine aminopeptidase 2)MetRS (Methionyl-tRNA synthetase)MGL (Methionine gamma-lyase)

Beyond the preview

Go deeper on trifluoromethionine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on trifluoromethionine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call